<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) is up 1.9% to trade at $632.42 at last check, after the drug maker posted a top- and bottom-line beat for its fourth quarter, which included revenues nearly doubling on sales of its Covid-19 antibody treatment, as well as higher demand for its Dupixent and Eylea drugs.
...read full article on Schaeffers Research
